title: [Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].
abstract: Thirty-65% of patients with metastatic lung cancer will develop bone metastasis. Bone metastases cause considerable skeletal morbidity, including bone pain, pathologic fractures, spinal cord compression and it is necessary to develop the effective treatment against bone metastasis. We reported cases of non-small-cell lung cancer who had dramatic improvements of pathologic fractures with gefitinib. In addition, gefitinib treatments elevated levels of serum Bone ALP, ICTP and ratio of Bone ALP/ICTP in patients with bone metastasis. Gefitinib may have inhibitory effects against bone resorption as well as antitumor effects.
authors: Japanese foundation for cancer research, Cancer institute hospital, Thracic Oncology Center.
authors: Yoshio
authors: Y
authors: Okano
authors: Makoto
authors: M
authors: Nishio
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D001862:Bone Resorption / Q000175:diagnosis; D024042:Collagen Type I; D005260:Female; D005598:Fractures, Spontaneous / Q000188:drug therapy / Q000209:etiology; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008875:Middle Aged; D010012:Osteogenesis; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides; D011347:Procollagen / Q000097:blood; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; D011799:Quinazolines; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; D000077156:Gefitinib